Stocktwits on MSN

KZIA stock is rising today — what does its data for nuclear PD-L1 degrader show?

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...
Becker's Hospital Review

FDA grants priority review to breast cancer drug

The FDA has granted priority review to the supplemental biologics license application for Datroway (datopotamab deruxtecan) in adults with unresectable or metastatic triple-negative breast cancer who ...
Nasdaq

Genprex Receives Notice of Allowance for Multiple Patents for Reqorsa® Gene Therapy with PD-L1 and PD-1 Antibodies to Treat Cancers

AUSTIN, Texas, Aug. 18, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients ...
The American Journal of Managed Care

Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...